Instrument Inactif

Communiqués Pfizer Inc NYSE

Actions

Produits pharmaceutiques

Cours en clôture NYSE Autres places de cotation
- ^USD	-

23/06	NIKE nomme David Denton, de Pfizer, au poste de nouveau directeur financier ; le titre progresse en après-Bourse	MT
23/06	NIKE nomme David Denton, de Pfizer, au poste de nouveau directeur financier	MT

Communiqués

23/06	Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts	BU
22/06	Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer	BU
18/06	Pfizer Announces Chief Financial Officer Transition	BU
08/06	U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need	BU
06/06	Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide	BU
01/06	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference	BU
31/05	Pfizer : BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer	PU
31/05	Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer	BU
30/05	TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer	BU
29/05	Pfizer : European Commission Authorizes Update to Pediatric Use of Pfizer and BioNTech COVID 19 Vaccine	PU
29/05	Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer	BU
29/05	Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines	BU
27/05	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference	BU
20/05	Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results	BU
13/05	European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors	BU
12/05	Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)	AQ
06/05	Pfizer : First Quarter 2026 Transcript	PU
05/05	Pfizer : Quarterly Corporate Performance - First Quarter 2026 Press Release	PU
05/05	Pfizer : Quarterly Corporate Performance - First Quarter 2026 Presentation	PU
05/05	Pfizer : Quarterly Corporate Performance - First Quarter 2026 Prepared Remarks	PU
05/05	Pfizer : First Quarter 2026 Earnings Teleconference	PU
05/05	Pfizer: Q1 Earnings Snapshot	AQ
05/05	Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance	BU
29/04	Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma	BU
28/04	Pfizer Reaches Three Settlement Agreements for VYNDAMAX	BU